Zynerba Pharmaceuticals ZYNE

$ 1.3 0.0%

Quarterly report 2023-Q2
added 08-14-2023

Zynerba Pharmaceuticals Balance Sheet 2011-2024 | ZYNE

Annual Balance Sheet Zynerba Pharmaceuticals

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-50.3 M	-67.2 M	-	-69.7 M	-59.8 M	-62.5 M	-31 M	-41.5 M	-9.33 M	345 K	-	-
Long Term Debt	120 K	354 K	-	-	-	-	-	-	-	375 K	-	-
Long Term Debt Current	215 K	209 K	110 K	244 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	110 K	-	662 K	-	-	16.5 M	1.5 M	-	-
Total Current Liabilities	9.17 M	9.9 M	13.9 M	12.1 M	9.73 M	7.44 M	6.97 M	3.94 M	-	-	-	-
Total Liabilities	9.29 M	10.3 M	13.9 M	12.2 M	9.73 M	8.1 M	6.97 M	3.94 M	19.7 M	3.06 M	-	-
Deferred Revenue	-	-	-	-	-	172 K	834 K	841 K	1.12 M	1.04 M	-	-
Retained Earnings	-275 M	-239 M	-202 M	-151 M	-118 M	-78 M	-46 M	-22.6 M	-10 M	-4.36 M	-	-
Total Assets	55.5 M	81.2 M	74.1 M	87.8 M	67.3 M	69.1 M	36.6 M	43.6 M	11.6 M	1.86 M	-	-
Cash and Cash Equivalents	50.6 M	67.8 M	59.2 M	70.1 M	59.8 M	62.5 M	31 M	41.5 M	9.33 M	155 K	-	-
Book Value	46.2 M	70.9 M	60.1 M	75.6 M	57.6 M	60.9 M	29.6 M	39.7 M	-8.05 M	-1.2 M	-	-
Total Shareholders Equity	46.2 M	70.9 M	60.1 M	75.6 M	57.6 M	60.9 M	29.6 M	39.7 M	-8.05 M	-4.36 M	-	-

All numbers in USD currency

Quarterly Balance Sheet Zynerba Pharmaceuticals

	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	60 K	120 K	179 K	237 K	296 K	354 K	411 K	468 K	525 K	-	-	-	44.2 K	110 K	110 K	110 K	110 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	11.5 M	9.67 M	9.29 M	9.61 M	9.77 M	9.21 M	10.3 M	11.3 M	10.5 M	13.1 M	13.9 M	13.9 M	13.9 M	13.9 M	12.2 M	12.2 M	12.2 M	12.2 M	9.73 M	9.73 M	9.73 M	9.73 M	8.1 M	8.1 M	8.1 M	8.1 M	6.97 M	5.41 M	-	-	3.94 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	172 K	-	172 K	172 K	834 K	834 K	834 K	834 K	834 K	834 K	834 K	841 K	841 K	841 K	841 K	1.12 M	1.12 M	1.12 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-295 M	-285 M	-275 M	-267 M	-258 M	-248 M	-239 M	-231 M	-220 M	-210 M	-202 M	-202 M	-202 M	-202 M	-151 M	-151 M	-151 M	-151 M	-118 M	-118 M	-118 M	-118 M	-78 M	-78 M	-78 M	-78 M	-46 M	-46 M	-46 M	-46 M	-22.6 M	-22.6 M	-22.6 M	-22.6 M	-10 M	-10 M	-10 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	40.5 M	48.6 M	55.5 M	62.4 M	67 M	74.4 M	81.2 M	90 M	98.2 M	109 M	74.1 M	74.1 M	74.1 M	74.1 M	87.8 M	87.8 M	87.8 M	87.8 M	67.3 M	67.3 M	67.3 M	67.3 M	69.1 M	69.1 M	69.1 M	69.1 M	36.6 M	36.6 M	36.6 M	36.6 M	43.6 M	43.6 M	43.6 M	43.6 M	11.6 M	11.6 M	11.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	36 M	44.4 M	50.6 M	55.9 M	62.5 M	69.7 M	67.8 M	75.6 M	85.8 M	93.1 M	59.2 M	59.2 M	59.2 M	59.2 M	70.1 M	70.1 M	70.1 M	70.1 M	59.8 M	59.8 M	59.8 M	59.8 M	62.5 M	62.5 M	62.5 M	62.5 M	31 M	31 M	31 M	31 M	41.5 M	41.5 M	41.5 M	41.5 M	9.33 M	9.33 M	9.33 M	-	155 K	-	-	-	166 K	-	-	-	-	-	-	-
Book Value	29 M	39 M	46.2 M	52.8 M	57.2 M	65.2 M	70.9 M	78.7 M	87.7 M	95.7 M	60.1 M	60.1 M	60.1 M	60.1 M	75.6 M	75.6 M	75.6 M	75.6 M	57.6 M	57.6 M	57.6 M	57.6 M	60.9 M	60.9 M	60.9 M	60.9 M	29.6 M	31.1 M	36.6 M	36.6 M	39.7 M	43.6 M	43.6 M	43.6 M	11.6 M	11.6 M	11.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	29 M	39 M	46.2 M	52.8 M	57.2 M	65.2 M	70.9 M	78.7 M	87.7 M	95.7 M	60.1 M	60.1 M	60.1 M	60.1 M	75.6 M	75.6 M	75.6 M	75.6 M	57.6 M	57.6 M	57.6 M	57.6 M	60.9 M	60.9 M	60.9 M	60.9 M	29.6 M	29.6 M	29.6 M	29.6 M	39.7 M	39.7 M	39.7 M	39.7 M	-8.05 M	-8.05 M	-8.05 M	-	-4.36 M	-	-	-	-3.56 M	-	-	-	-	-	-	-

All numbers in USD currency